Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Semaxanib (SUGEN).

K M Sakamoto1

  • 1UCLA School of Medicine, Department of Pediatrics and Pathology, 10833 LeConte Avenue, Los Angeles, CA 90095-1752, USA. kms@ucla.edu

Idrugs : the Investigational Drugs Journal
|June 21, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diamond Blackfan anemia is mediated by hyperactive Nemo-like kinase.

Nature communications·2020
Same author

Perspective on Diamond-Blackfan anemia: lessons from a rare congenital bone marrow failure syndrome.

Leukemia·2017
Same author

Small molecule inhibition of cAMP response element binding protein in human acute myeloid leukemia cells.

Leukemia·2016
Same author

The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia.

Leukemia·2016
Same author

Replication factor C3 is a CREB target gene that regulates cell cycle progression through the modulation of chromatin loading of PCNA.

Leukemia·2014
Same author

Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer.

Oncogene·2008
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Semaxanib (SU-5416) is a small molecule inhibitor targeting the flk-1 tyrosine kinase receptor, investigated for treating solid tumors by inhibiting metastasis and angiogenesis. Phase III trials were initiated for colorectal and lung cancers, with potential combination therapies explored.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Semaxanib (SU-5416) is a small molecule inhibitor targeting the fms-like tyrosine kinase 1 (flk-1) receptor tyrosine kinase (RTK).
  • The flk-1 RTK plays a crucial role in angiogenesis and metastasis, making it a target for anti-cancer therapies.
  • SUGEN, owned by Pharmacia, is developing semaxanib for the potential treatment of various solid tumors.

Purpose of the Study:

  • To evaluate the efficacy of semaxanib in treating solid tumors.
  • To investigate semaxanib's potential in suppressing tumor metastasis and angiogenesis.
  • To assess semaxanib as a potential addition to standard chemotherapy regimens.

Main Methods:

  • Initiation of Phase III clinical trials for colorectal and lung cancers in July 1999.

Related Experiment Videos

  • Initiation of Phase III trials for semaxanib as an adjunct to standard chemotherapy in colorectal cancer in March 2001.
  • Evaluation of oral formulations of semaxanib.
  • Joint development program established between Taiho and SUGEN for angiogenesis inhibitors.

    • Main Results:

    • Phase III trials for colorectal and lung cancers were initiated.
    • Clinical studies were conducted by Pharmacia and the NCI for numerous solid and hematological cancers.
    • Oral forms of semaxanib were under evaluation.
    • Pharmacia anticipated US and international filing in 2001.

    Conclusions:

    • Semaxanib demonstrated potential as a therapeutic agent for solid tumors.
    • The compound's ability to suppress metastasis and angiogenesis supports its anti-cancer properties.
    • Ongoing clinical trials and patent filings indicate significant development progress.